SCHEMBL4122030

SCHEMBL4122030

CNCc1ccc(-c2ncnc3c2ncn3C2CCCCO2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
CYP2C19 P33261 1/20 0.55
CYP1A2 P05177 2/20 0.53
TSHR P16473 1/20 0.53
TP53 P04637 1/20 0.50
CYP2C9 P11712 1/20 0.50
NFKB1 P19838 1/20 0.50
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
APEX1 P27695 1/20 0.50
PI4KA P42356 1/20 0.50
BLM P54132 1/20 0.50
KMT2A Q03164 1/20 0.50
ADCY1 Q08828 1/20 0.50
PI4K2B Q8TCG2 1/20 0.50
PI4K2A Q9BTU6 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4063305 0.86 CYP1A2 (0.53) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2
SCHEMBL4137893 0.84 CYP1A2 (0.54) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2
SCHEMBL4134543 0.81 CYP2C19 (0.57) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2
SCHEMBL4067215 0.77 NPC1 (0.57) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2
SCHEMBL4070092 0.77 NPC1 (0.54) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2
SCHEMBL22111670 0.77 CYP2C19 (0.52) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2
SCHEMBL22111671 0.76 CYP2C19 (0.51) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2
SCHEMBL4063885 0.76 CYP1A2 (0.56) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2
SCHEMBL5732305 0.76 NPC1 (0.45) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2
SCHEMBL5732302 0.76 NPC1 (0.45) NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253718-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS LIMITED (GB) 2009-10-08 US disclosed
US-20090253718-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS LIMITED (GB) 2009-10-08 US disclosed
US-20090099213-A1 Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2009-04-16 US disclosed
US-20090099213-A1 Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2009-04-16 US disclosed
EP-2016077-A2 PHARMACEUTICAL COMPOUNDS Astex Therapeutics Limited (GB) 2009-01-21 EP disclosed
WO-2007125315-A2 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2007-11-08 WO disclosed
WO-2007125315-A2 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253718-A1 Pharmaceutical Compounds GRK3, CNKSR1, CSNK1G3 NPC1 1129/4885RAB9A 1693/4885SMN1; SMN2 1448/4885
US-20090099213-A1 Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors OXSR1, CDK1, CDK3 NPC1 3269/4885RAB9A 3680/4885SMN1; SMN2 3006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.